|Phase transitions in biogenic amorphous calcium carbonate|
YUT Gong, CE Killian, IC Olson, NP Appathurai, AL Amasino, MC Martin, ...
Proceedings of the National Academy of Sciences 109 (16), 6088-6093, 2012
|Mechanism of calcite co-orientation in the sea urchin tooth|
CE Killian, RA Metzler, YUT Gong, IC Olson, J Aizenberg, Y Politi, FH Wilt, ...
Journal of the American Chemical Society 131 (51), 18404-18409, 2009
|Self‐Sharpening Mechanism of the Sea Urchin Tooth|
CE Killian, RA Metzler, Y Gong, TH Churchill, IC Olson, V Trubetskoy, ...
Advanced Functional Materials 21 (4), 682-690, 2011
|Prognostic value of the lung immune prognostic index for patients treated for metastatic non–small cell lung cancer|
D Kazandjian, Y Gong, P Keegan, R Pazdur, GM Blumenthal
JAMA oncology 5 (10), 1481-1485, 2019
|Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton …|
T Giaddui, W Chen, J Yu, L Lin, CB Simone, L Yuan, YUT Gong, QJ Wu, ...
Radiation oncology 11 (1), 1-7, 2016
|FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1|
P Narayan, S Wahby, JJ Gao, L Amiri-Kordestani, A Ibrahim, E Bloomquist, ...
Clinical cancer research 26 (10), 2284-2289, 2020
|Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer|
GM Blumenthal, Y Gong, K Kehl, P Mishra-Kalyani, KB Goldberg, ...
Annals of Oncology 30 (5), 830-838, 2019
|FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma|
E Chang, C Weinstock, L Zhang, R Charlab, SE Dorff, Y Gong, V Hsu, F Li, ...
Clinical Cancer Research 27 (4), 922-927, 2021
|FDA approval summary: olaparib monotherapy or in combination with Bevacizumab for the maintenance treatment of patients with advanced ovarian cancer|
S Arora, S Balasubramaniam, H Zhang, T Berman, P Narayan, D Suzman, ...
The Oncologist 26 (1), e164-e172, 2021
|Validation of a rectal cancer outcome prediction model with a cohort of Chinese patients|
L Shen, J van Soest, J Wang, J Yu, W Hu, YUT Gong, V Valentini, Y Xiao, ...
Oncotarget 6 (35), 38327, 2015
|FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer|
P Narayan, TM Prowell, JJ Gao, LL Fernandes, E Li, X Jiang, J Qiu, J Fan, ...
Clinical Cancer Research 27 (7), 1842-1849, 2021
|Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials|
Y Gong, KL Kehl, GR Oxnard, S Khozin, PS Mishra-Kalyani, ...
Journal of Clinical Oncology 36 (suppl), abstr 9064, 2018
|FDA approval summary: tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer|
M Shah, S Wedam, J Cheng, MH Fiero, H Xia, F Li, J Fan, X Zhang, J Yu, ...
Clinical Cancer Research 27 (5), 1220-1226, 2021
|Exploration of baseline derived neutrophil to lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC …|
DG Kazandjian, Y Gong, H Kazandjian, R Pazdur, GM Blumenthal
Journal of Clinical Oncology 36 (suppl), abstr 3035, 2018
|FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer|
JJ Gao, CL Osgood, Y Gong, H Zhang, EW Bloomquist, X Jiang, J Qiu, ...
Clinical Cancer Research 27 (8), 2126-2129, 2021
|FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer|
MS Anscher, E Chang, X Gao, Y Gong, C Weinstock, E Bloomquist, ...
The oncologist 26 (2), 139-146, 2021
|An Analysis of Recent FDA Oncology Scientific Publications|
JA Schneider, AC Miklos, J Onken, Y Gong, AM Calcagno, ...
The oncologist 25 (3), 266, 2020
|Automated Extraction of Dose/Volume Statistics for Radiotherapy-Treatment-Plan Evaluation in Clinical-Trial Quality Assurance|
Y Gong, J Yu, D Pang, H Zhen, J Galvin, Y Xiao
Frontiers in Oncology 6, 2016
|Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation …|
DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ...
European Journal of Cancer 157, 140-152, 2021
|Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health|
E Chang, L Pelosof, S Lemery, Y Gong, KB Goldberg, AT Farrell, ...
The oncologist 26 (10), e1786-e1799, 2021